These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 16093511)

  • 1. Ryanodine receptor-targeted anti-arrhythmic therapy.
    Wehrens XH; Lehnart SE; Marks AR
    Ann N Y Acad Sci; 2005 Jun; 1047():366-75. PubMed ID: 16093511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcoplasmic reticulum calcium leak and cardiac arrhythmias.
    Chelu MG; Wehrens XH
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):952-6. PubMed ID: 17956253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights.
    Kontula K; Laitinen PJ; Lehtonen A; Toivonen L; Viitasalo M; Swan H
    Cardiovasc Res; 2005 Aug; 67(3):379-87. PubMed ID: 15913575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ryanodine receptors and ventricular arrhythmias: emerging trends in mutations, mechanisms and therapies.
    George CH; Jundi H; Thomas NL; Fry DL; Lai FA
    J Mol Cell Cardiol; 2007 Jan; 42(1):34-50. PubMed ID: 17081562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac ryanodine receptor function and regulation in heart disease.
    Lehnart SE; Wehrens XH; Kushnir A; Marks AR
    Ann N Y Acad Sci; 2004 May; 1015():144-59. PubMed ID: 15201156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves.
    Paavola J; Viitasalo M; Laitinen-Forsblom PJ; Pasternack M; Swan H; Tikkanen I; Toivonen L; Kontula K; Laine M
    Eur Heart J; 2007 May; 28(9):1135-42. PubMed ID: 17347175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia.
    Marks AR; Priori S; Memmi M; Kontula K; Laitinen PJ
    J Cell Physiol; 2002 Jan; 190(1):1-6. PubMed ID: 11807805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapy for heart failure and exercise-induced ventricular tachycardia based on 'fixing' the leak in ryanodine receptors.
    Marks AR
    Novartis Found Symp; 2006; 274():132-47; discussion 147-55, 272-6. PubMed ID: 17019810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ryanodine receptor as a Ca²(+) regulatory center in normal and failing hearts.
    Yano M; Yamamoto T; Kobayashi S; Matsuzaki M
    J Cardiol; 2009 Feb; 53(1):1-7. PubMed ID: 19167631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal ryanodine receptor function in heart failure.
    Yano M; Yamamoto T; Ikemoto N; Matsuzaki M
    Pharmacol Ther; 2005 Sep; 107(3):377-91. PubMed ID: 15951021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ca2+/calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2+ leak in heart failure.
    Ai X; Curran JW; Shannon TR; Bers DM; Pogwizd SM
    Circ Res; 2005 Dec; 97(12):1314-22. PubMed ID: 16269653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of abnormal calcium homeostasis in mutations responsible for catecholaminergic polymorphic ventricular tachycardia.
    Iyer V; Hajjar RJ; Armoundas AA
    Circ Res; 2007 Feb; 100(2):e22-31. PubMed ID: 17234962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Disease: ryanodine receptor defects in heart failure and fatal arrhythmia.
    Yano M; Yamamoto T; Ikeda Y; Matsuzaki M
    Nat Clin Pract Cardiovasc Med; 2006 Jan; 3(1):43-52. PubMed ID: 16391617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of ryanodine receptor mutations in cardiac pathology: more questions than answers?
    Thomas NL; George CH; Lai FA
    Biochem Soc Trans; 2006 Nov; 34(Pt 5):913-8. PubMed ID: 17052226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia.
    Mohamed U; Napolitano C; Priori SG
    J Cardiovasc Electrophysiol; 2007 Jul; 18(7):791-7. PubMed ID: 17578347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
    J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arrhythmogenic mutation-linked defects in ryanodine receptor autoregulation reveal a novel mechanism of Ca2+ release channel dysfunction.
    George CH; Jundi H; Walters N; Thomas NL; West RR; Lai FA
    Circ Res; 2006 Jan; 98(1):88-97. PubMed ID: 16339485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sarcoplasmic reticulum and arrhythmogenic calcium release.
    Venetucci LA; Trafford AW; O'Neill SC; Eisner DA
    Cardiovasc Res; 2008 Jan; 77(2):285-92. PubMed ID: 18006483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ryanodine receptors for anti-arrhythmic therapy.
    McCauley MD; Wehrens XH
    Acta Pharmacol Sin; 2011 Jun; 32(6):749-57. PubMed ID: 21642946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ryanodine receptor mutations in arrhythmias: advances in understanding the mechanisms of channel dysfunction.
    Thomas NL; George CH; Williams AJ; Lai FA
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):946-51. PubMed ID: 17956252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.